PAN-CHEMOKINE ANTAGONISTS FOR USE IN TREATING CANCER AND IMMUNE DISORDERS

Abstract: a chemical compound 2-({6-phenylthieno[2,3-d]pyrimidin-4-yl}oxy)benzamide for use as a ccr7 (c-c chemokine receptor type 7) antagonist. it is also a pan-chemokine antagonist and has an antagonistic effect to ccr1, ccr2, ccr3, ccr5, ccr9 and cxcr4 chemokine receptors for use in the prevention of metastatsis formation in lung, liver and ribs in in vivo mice breast cancer model. also described are chemical compounds 3-chloro-2-{[6-(2-chlorophenyl)-2,5-dimethylthieno[2,3-d]pyrimidin-4-yl]oxy}benzamide and 3-chloro-2-{[6-(2-chlorophenyl)-2-methylthieno[2,3-d]pyrimidin-4-yl]oxy}benzamide, as pan-chemokine antagonists. these compounds are for use in the prevention or treatment of: (i) diseases associated with chemokine receiptors which are, specifically, lung, liver, ribs and lymph node metastasis and the progression of many different malignancies such as breast, gastric, skin (melanoma), head and neck, lung, esophageal, hepatocellular, cervical, thyroid, tonsillar, colorectal and prostate cancers; (ii) virus infection diseases associated with chemokine receptors such as hiv-1, hiv-2, sars-cov-2 (covid-19); and (iii) the immune related diseases such as psoriasis, arthritis and atopic demiatitis.

Inventor(s): Filip Filipov FRATEV

CPC Classification: C07D495/04 (HETEROCYCLIC COMPOUNDS (macromolecular compounds ))

Search for rejections for patent application number 20250206754